Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Somatix GVAX

Executive Summary

Somatix GVAX: Phase I trials with the genetically-engineered GVAX cancer vaccine in patients with advanced malignant melanoma show the vaccine is well-tolerated and stimulates an immune response, clinical investigators report at the American Society of Clinical Oncologists May 22 in Los Angeles. Ten patients have received the full course of vaccinations of three vaccinations over two months, and three patients' disease has been stabilized for eight months or more. The vaccine is composed of a patient's own cells genetically modified with the gene for the immunostimulant GM-CSF, Somatix reports...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel